1 min.Read

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

May 15, 2025

In a bold move to strengthen its hepatology pipeline, GlaxoSmithKline (GSK) has announced a deal worth up to $2 billion to acquire efimosfermin, a promising treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH), from Boston Pharmaceuticals.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Topics

Indian Pharma Market Performance – April 2025

Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

Free Membership Required

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Pharmacy of the World Pricing Paradox

Topics

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Pharmacy of the World Pricing Paradox

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

MedicinMan Pharma Pulse: August 2026

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

Related Articles

India’s Pharma Renaissance: Private Equity at the Helm

Indian Pharma November Sales: What Do They Say?

Genome Valley: A Signal of Transformation in Indian Pharma?

Biocon Bats for Affordable Insulin and Ozempic

Indian Pharma Power 23

Company

Headlines

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Newsletter